UY28815A1 - Agentes terapéuticos - Google Patents

Agentes terapéuticos

Info

Publication number
UY28815A1
UY28815A1 UY28815A UY28815A UY28815A1 UY 28815 A1 UY28815 A1 UY 28815A1 UY 28815 A UY28815 A UY 28815A UY 28815 A UY28815 A UY 28815A UY 28815 A1 UY28815 A1 UY 28815A1
Authority
UY
Uruguay
Prior art keywords
disorders
therapeutic agents
disease
compounds
chorea
Prior art date
Application number
UY28815A
Other languages
English (en)
Inventor
Egner Bryan
Giordanetto Fabrizzio
Inghardt Tord
Linusson Anna
Ponten Fritiof
Brickmann Kay
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34993625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28815(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0400718A external-priority patent/SE0400718D0/xx
Priority claimed from SE0402780A external-priority patent/SE0402780D0/sv
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY28815A1 publication Critical patent/UY28815A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Compuestos de fórmula I, procesos para preparar tales compuestos, su uso en el tratamiento de la obesidad, trastornos psiquiátricos, trastornos cognitivos, de memoria, esquizofrenia, epilepsia, y afecciones relacionadas, y trastornos neurológicos como demencia, esclerosis múltiple, mal de Parkinson, corea de Huntington y mal de Alzheimer y trastornos relacionados con el dolor y a composiciones farmacéuticas que los contienen.
UY28815A 2004-03-22 2005-03-21 Agentes terapéuticos UY28815A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0400718A SE0400718D0 (sv) 2004-03-22 2004-03-22 Therapeutic agents
SE0402780A SE0402780D0 (sv) 2004-11-12 2004-11-12 Therapeutic agents

Publications (1)

Publication Number Publication Date
UY28815A1 true UY28815A1 (es) 2005-11-30

Family

ID=34993625

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28815A UY28815A1 (es) 2004-03-22 2005-03-21 Agentes terapéuticos

Country Status (15)

Country Link
US (1) US20080300232A1 (es)
EP (1) EP1730136A1 (es)
JP (1) JP2007530533A (es)
KR (1) KR20070007341A (es)
AR (1) AR048319A1 (es)
AU (1) AU2005223727A1 (es)
BR (1) BRPI0508952A (es)
CA (1) CA2558058A1 (es)
IL (1) IL177729A0 (es)
MX (1) MXPA06010754A (es)
NO (1) NO20064752L (es)
RU (1) RU2006135486A (es)
TW (1) TW200538098A (es)
UY (1) UY28815A1 (es)
WO (1) WO2005090330A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595571A (en) * 2006-02-28 2013-04-26 Helicon Therapeutics Inc Pyrazole compounds and uses thereof
US8592435B2 (en) 2007-04-27 2013-11-26 Daiichi Sankyo Company, Limited Nitrogen-containing six-membered aromatic ring derivatives and pharmaceutical products containing the same
MX2010002258A (es) 2007-08-27 2010-04-22 Helicon Therapeutics Inc Compuestos terapeuticos de isoxazol.
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
KR20130041177A (ko) 2010-07-06 2013-04-24 아스트라제네카 아베 치료제 976
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
US20160214967A1 (en) * 2013-09-30 2016-07-28 The University Of Tokyo Activator of adiponectin receptor
US20180305334A1 (en) * 2015-10-14 2018-10-25 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
CN110636844A (zh) * 2017-04-05 2019-12-31 万能溶剂有限公司 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物
JP2022502441A (ja) * 2018-09-26 2022-01-11 アルカヘスト，インコーポレイテッド Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501898A (ja) * 1998-02-02 2002-01-22 メルク エンド カムパニー インコーポレーテッド ケモカイン受容体活性の環状アミン調節剤
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
GB0104050D0 (en) * 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
CA2445348A1 (en) * 2001-04-27 2002-11-07 Mitsubishi Pharma Corporation Novel benzylpiperidine compound
SE0200919D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
US6921821B2 (en) * 2002-06-12 2005-07-26 Abbott Laboratories Antagonists of melanin concentrating hormone receptor

Also Published As

Publication number Publication date
AU2005223727A1 (en) 2005-09-29
WO2005090330A1 (en) 2005-09-29
US20080300232A1 (en) 2008-12-04
BRPI0508952A (pt) 2007-08-14
CA2558058A1 (en) 2005-09-29
IL177729A0 (en) 2006-12-31
MXPA06010754A (es) 2006-12-15
AR048319A1 (es) 2006-04-19
RU2006135486A (ru) 2008-04-27
NO20064752L (no) 2006-11-20
JP2007530533A (ja) 2007-11-01
TW200538098A (en) 2005-12-01
EP1730136A1 (en) 2006-12-13
KR20070007341A (ko) 2007-01-15

Similar Documents

Publication Publication Date Title
UY28815A1 (es) Agentes terapéuticos
UY29673A1 (es) Derivados sustituidos de 6-(4-clorofenil) tieno (3,2,d)- pirimidin- 4(3h)-ona y (1,2,3,)-triazin-4-(3h)-ona,composiciones farmaceuticas conteniéndolos, procesosde peparación y aplicaciones.
UY28374A1 (es) Agentes terapéuticos
UY28752A1 (es) Agentes terapeuticos
UY28144A1 (es) Agentes terapéuticos
TW200635589A (en) Therapeutic agents
AR038047A1 (es) Agentes terapeuticos
UY28376A1 (es) Agentes terapéuticos
UY28839A1 (es) Agentes terapeuticos
UY28150A1 (es) Agentes terapeuticos
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
PA8627201A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
ECSP077275A (es) Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
CU20090184A7 (es) Compuestos amino-heterocíclicos
TW200635903A (en) Therapeutic agents
ECSP088366A (es) 1,2-diarilimidazoles para uso como moduladores de cb1
TW200633986A (en) Therapeutic agents
ECSP034810A (es) Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6
UY28484A1 (es) Compuestos para el tratamiento de trastornos neurodegenerativos
IL179160A0 (en) Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
BRPI0418181A (pt) emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson
AR028624A1 (es) Heterociclilalquilaminas como antagonistas de receptores muscarinicos
UY28377A1 (es) Agentes terapeuticos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160502